A Randomized Phase III Trial Comparing Trabectedin (Yondelis®) to the Best Supportive Care in Patients With Advanced Soft Tissue Sarcoma

Trial Profile

A Randomized Phase III Trial Comparing Trabectedin (Yondelis®) to the Best Supportive Care in Patients With Advanced Soft Tissue Sarcoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Trabectedin (Primary) ; Dexamethasone
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms TSAR
  • Sponsors Gustave Roussy cancer campus
  • Most Recent Events

    • 11 Oct 2016 Primary endpoint (Progression Free Survival) has been met,according to the results published at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress (2016).
    • 11 Oct 2016 Status changed from recruiting to active, no longer recruiting,according to the results published at the 41st European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top